Content area
Abstract
In a session on new antimicrobials in the pipeline, Daniel Vlock, Chief Executive Officer of Alopexx (Concord, MA, USA), presented preclinical and early clinical data on F598, a novel, fully human, broad-spectrum monoclonal antibody (mAb) targeting poly-N-acetyl glucosamine (PNAG). In a session on upcoming Infectious Diseases Society of America Clinical Practice Guidelines, Barbara Trautner (Baylor College of Medicine, Houston, TX, USA) and Nicolás Cortés-Penfield (University of Nebraska Medical Center, Omaha, NE, USA) gave a sneak peak into the first-ever Clinical Practice Guidelines for the treatment of complicated urinary tract infections (cUTIs) in adults. Regarding the Clinical Practice Guidelines for complicated urinary tract infection, the Infectious Diseases Society of America (IDSA) emphasises that the guideline is still in draft form and that clinicians should not implement any of the recommendations described in this report until the guideline is finalised.